Introduction {#sec1-1}
============

Significant left main coronary artery (LMCA) thrombosis has a 40%--80% mortality, and the treatment strategy is determined from experience in LMCA stenosis in nonacute cases ([@ref1]). Coronary revascularization guidelines lack clear Class I suggestion for the management of prosthetic valve thrombosis owing to the lack of randomized trials and leave the choice of treatment to physicians ([@ref2]). Here we describe a treatment approach used in a patient with combined LMCA thrombosis and PVT.

Case Report {#sec1-2}
===========

A 41-year-old woman with irregular warfarin use and mechanical mitral valve replacement performed 2 years previously presented to the emergency department with chest pain, dyspnea, widespread ST depression on electrocardiography, and an international normalized ratio (INR) of 1.3. She was referred for primary percutaneous coronary intervention (PCI) because she was on inotropes, was hypoxic, and in cardiogenic shock. Thrombotic occlusion of the LMCA, left anterior descending (LAD) and circumflex (CX) arteries, and normal right coronary artery (RCA) was observed upon perfroming angiography ([Fig. 1](#F1){ref-type="fig"}).

![Massive thrombus in LMCA extending into the LAD and CX ostia with normal RCA](AJC-20-365-g001){#F1}

Emergent echocardiography revealed an ejection fraction of 20% and a normal prosthetic valve; however, the obtained images were suboptimal owing to patient movement and inability for positioning. Aspirin (100 mg), Clopidogrel (600 mg), and heparin (7500 IU) was given, and a 6-Fr JL 3.5 guide catheter was inserted through the transfemoral route. LAD and CX were easily wired with floppy guidewire. We first tried aspiration using a 6-Fr Medtronic Export aspiration catheter from LMCA to LAD and later from LMCA to CX; however, the catheter was always clogged with white dense fibrotic thrombus. The flow did not improve despite using the aspiration catheter; however, the thrombus was dispersed into the LAD and Cx. We then ballooned the LAD and Cx with a 2.5×20-mm sized Simpass balloon, which restored the flow in both arteries. We observed that the thrombus in the LAD was very dense and not retrievable; hence, we stented the LAD with a Xcience 3.5×34 mm-sized stent to exclude the thrombus from the lumen. TIMI III flow was obtained in the LAD; however, distal LMCA, LAD ostium, and CX ostium had residual thrombi. We decided upon V stenting of the LMCA--LAD--CX bifurcation and advanced two stents to related vessels; however, suddenly, the thrombus disappeared, and the stents were retrieved back without implantation. The CX distal embolic material was dispersed with floppy guidewire and the procedure was completed ([Fig. 2](#F2){ref-type="fig"}).

![TIMI III flow in LAD with residual thrombi in distal LMCA, LAD ostium, and CX ostium on the left. Disapperance of the thrombus while preparing for V stenting in the middle. Final angiography showing only residual distal Cx embolization at the end of the procedure on the right](AJC-20-365-g002){#F2}

IABP was inserted, and the patient was followed-up with high doses of dopamin, noradrenalin, and heparin infusions. One mitral leaflet was seen to be thrombosed and stuck in the echocardiography perfromed the next day. Mitral valve reoperation was assessed as high risk; hence, tissue plasminogen activator (tPA) was given at a dose of 25 mg over 24 hours. The next day, transesophageal echocardiography (TEE) revealed mobile leaflet with residual thrombus. We continued another 25 mg tPA infusion over the next 24 hours. TEE imaging after 2 days revealed a completely functional mitral valve. Four days later, the IABP was removed and the inotropes were weaned. Transthoracic echocardiography was repeated, and the mitral leaflet was found to be stuck again. Another 25 mg of tPA infusion over 24 hours was given, and the leaflet movement returned to normal again the next day ([Fig. 3](#F3){ref-type="fig"}). Her pneumonia was treated with antibiotics and she was discharged on aspirin (100 mg), clopidogrel (75 mg), and warfarin (5 mg/day).

![Stuck mitral leaflet on the left and normal leaflet motion after thrombolytics](AJC-20-365-g003){#F3}

Discussion {#sec1-3}
==========

Coronary embolisation is also seen in PVT, and generally, acute coronary syndrome is considered due to PVT-related embolism ([@ref3]). Thrombolytic therapy may be considered for both coronary and valve thrombosis in hemodynamically stable patients ([@ref4]). The superiority of surgery or thrombolytics is not clear due to the head-to-head randomized controlled trial; however, low-dose slow infusion of tPA repeated as needed without a bolus provides effective and safe thrombolysis in patients with prosthetic valve thrombosis ([@ref2], [@ref5]). In a previous case series, thrombolytic therapy was also successfull in the treatment of combined valve thrombosis and coronary embolism ([@ref6]).

In our patient, we used the low dose-prolonged infusion protocol instead of the conventional tPa infusion due to bleeding risk. The TROIA study reported successful thrombolysis in 83.2% of cases in low-dose slow infusion without a significant difference between the thrombolytic protocols ([@ref5]).

Conclusion {#sec1-4}
==========

Acute thrombotic LMCA occlusion is a catastrophic event, and during intervention, the cardiologist needs to use percutaneous transluminal coronary angioplasty, thrombus aspiration, different stenting techniques, thrombolytics, and IABP support in different combinations. In LMCA thrombosis, prosthetic valves should be carefully evaluated for the presence and function of thrombus with TEE and fluoroscopy.
